1.
患者治疗及生存情况
Data of treatments and outcomes of the 10 patients with relapsed or refractoryextranodal NK/T cell lymphoma
| No | Gender | Age (year) | Diagnosis/staging /Primary site | Lnitialtreatment | Pg-GEOX-RT | Effect | PFS (d) | OS (d) | CurrentStatus |
| CHOP: Cyclophosphamide, doxorubicin, vincristine and prednisone; COP-R: Cyclophosphamide, doxorubicin, prednisone and radiotherapy; SMILE: Dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; VIPD: Etoposide, ifosfamide, cisplatin, dexamethasone; DICE: Cisplatin, ifosfamide, etoposide, dexamethasone; Pg-GEOX-RT: Pegaspargase, gemcitabine, oxaliplatin and radiotherapy; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease. | |||||||||
| 1 | Female | 35 | ENKL/Ⅱ/Jejunum | 6CHOP-R | 6 | SD | 221 | 456 | Relapse |
| 2 | Male | 65 | ENKL/Ⅳ/Nasal cavity | 3DICE | 3 | PD | 132 | 169 | Dead |
| 3 | Male | 49 | ENKL/Ⅲ/Nasal cavity | 2VIPD | 4 | PR | 169 | 169 | Live |
| 4 | Male | 27 | ENKL/Ⅱ/Nasal cavity | 3SMILE | 5 | CR | 258 | 258 | Live |
| 5 | Female | 39 | ENKL/Ⅲ/Lung | 5COP-R | 3 | PD | 109 | 169 | Dead |
| 6 | Male | 25 | ENKL/Ⅱ/Nasal cavity | 3SMILE | 3 | CR | 234 | 234 | Live |
| 7 | Male | 33 | ENKL/Ⅳ/Jejunum | 6SMILE | 4 | PD | 76 | 141 | Dead |
| 8 | Male | 6° | ENKL/Ⅳ/Nasal cavity | 2CHOP-R | 2 | PD | 58 | 95 | Dead |
| 9 | Male | 46 | ENKL/Ⅳ/Nasal cavity | 3SMILE | 3 | PD | 92 | 152 | Dead |
| 10 | Female | 38 | ENKL/Ⅲ/Nasal cavity | 5SMILE | 2 | PD | 194 | 259 | Dead |